Esophageal carcinoma: current controversies.
The incidence of esophageal adenocarcinoma and adenocarcinoma of the gastric cardia has increased so substantially in the last two decades that adenocarcinoma now accounts for approximately one half of esophageal malignancies seen in the United States and Europe. The reasons for this histological change may be related to a parallel increase in the incidence of gastroesophageal reflux disease in the Western world and the subsequent development of Barrett's metaplasia. Controversies surrounding carcinoma of the esophagus that are currently the focus of study are the relationship of Barrett's esophagus to the development of adenocarcinoma; whether adenocarcinoma of the esophagus and cardia is the same disease; the correct way to stage the disease; the treatment of disease confined to the mucosa; the extent of surgical resection to cure disease beyond the mucosa; the role of adjuvant chemotherapy in the treatment of the disease; and the methods of palliating patients with incurable disease.
DeMeester
T R
TR
University of Southern California School of Medicine, Division of Cardiovascular and Thoracic Surgery, Los Angeles 90033-4612, USA.
D000230:Adenocarcinoma / Q000175:diagnosis* / Q000209:etiology* / Q000628:therapy; D001471:Barrett Esophagus / Q000150:complications* / Q000175:diagnosis; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D002299:Cardia; D003131:Combined Modality Therapy; D003937:Diagnosis, Differential; D004938:Esophageal Neoplasms / Q000175:diagnosis* / Q000209:etiology* / Q000628:therapy; D006801:Humans; D009367:Neoplasm Staging; D010166:Palliative Care; D011379:Prognosis; D013274:Stomach Neoplasms / Q000175:diagnosis* / Q000209:etiology